scholarly journals Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial

2021 ◽  
Author(s):  
Ying Cheng ◽  
Qiming Wang ◽  
Kai Li ◽  
Jianhua Shi ◽  
Lin Wu ◽  
...  
1987 ◽  
Vol 5 (2) ◽  
pp. 255-259 ◽  
Author(s):  
S W Hansen ◽  
F Jensen ◽  
N T Pedersen ◽  
A G Pedersen ◽  
H H Hansen

Liver evaluation of 131 patients with small-cell lung cancer (SCLC) was performed both by peritoneoscopy (PS) with liver biopsy and by ultrasonography (US) with fine-needle aspiration. A total of 33 patients (25%) had liver involvement, 82% detected by US and 76% detected by PS. The difference was due to 27 incomplete investigations by PS and two incomplete investigations by US. In 104 patients in whom both investigations were "successful," PS confirmed 86% and US confirmed 79% of the patients with liver metastases. In each of the investigations, 7% (PS) and 14% (US) of patients had false-negative conclusions as compared with histologic evidence obtained by the other method. US found six patients with extrahepatic intraabdominal disease, while PS found none. S-lactic dehydrogenase (s-LDH), SGOT, and s-alkaline phosphatase were found to be too unspecific to indicate liver metastases unless all three tests were normal or abnormal. It is recommended that US should be used as the initial procedure when staging patients with SCLC, and that PS can be considered complementary in patients with negative US.


Sign in / Sign up

Export Citation Format

Share Document